Company / Depreciation & Amortization
Jazz Pharmaceuticals Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$41.6M
FY2025
5-year range
$15.3M / $41.6M
FY2021-FY2025
Trend
+26.8%
vs FY2024
Sector context
#33 of 163
Health Care
What the data says
Jazz Pharmaceuticals's depreciation & amortization of $42M is higher than 80% of companies in the Health Care sector (FY2025). Depreciation & Amortization has increased for 7 consecutive years, from $12M in FY2018 to $42M in FY2025.
Based on SEC 10-K filings.
$42M in FY2025 with a 5-year CAGR of +22.3%. Top quartile in the Health Care sector.
Increased from $30M to $42M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +30.5%
- 5-Year CAGR
- +22.3%
- 10-Year CAGR
- -
Sector benchmark
-81.0% below sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's depreciation & amortization has grown for 7 consecutive years.
- 5-year CAGR of +22.3%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 26.8% year-over-year.
- Ranks #33 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.6M | +26.8% |
| FY2024 | $32.8M | +7.9% |
| FY2023 | $30.4M | +62.6% |
| FY2022 | $18.7M | +22.2% |
| FY2021 | $15.3M | +0.7% |
| FY2020 | $15.2M | +16.0% |
| FY2019 | $13.1M | +11.0% |
| FY2018 | $11.8M | -9.9% |
| FY2017 | $13.1M | +84.6% |
| FY2016 | $7.1M | -28.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026